Sep 25, 2023 Private Equity in the Antitrust Spotlight By Angela Landry Emily Strickland On September 21, the Federal Trade Commission (“FTC”) filed a suit against a private equity firm and one of its portfolio companies,...
Aug 22, 2023 M&A Buyers Beware: Trend in Delaware Merits Heightened Attention by Acquirors By Ethan Klingsberg Victor Ma A trio of recent, high-profile M&A cases in the Delaware Court of Chancery merit special attention by M&A acquirors. In each of these...
Aug 11, 2023 President Biden Issues Outbound Investment Restrictions Executive Order – Small Yard, High Fence? By Aimen Mir Christine Laciak Colin Costello Timothy Swartz Mark Appleton +2 more... Show less On Wednesday, August 9, 2023, President Biden issued Executive Order 14105, Addressing United States Investments in Certain National...
Jul 20, 2023 Proposed New U.S. Merger Guidelines: Making Old Ideas New Again By Bruce McCulloch Andrew Ewalt Jamillia Ferris Mary Lehner Jennifer Mellott Meghan Rissmiller Jan Rybnicek Justin Stewart-Teitelbaum Laura Onken Timothy Swartz +7 more... Show less The U.S. Department of Justice Antitrust Division (“DOJ”) and Federal Trade Commission (“FTC”) yesterday released a draft of revised...
Jun 07, 2023 Return of the CVR By Adam Golden Mark Appleton The recent surge in bolt-on M&A in the life sciences sector is being fueled by the use of contingent value rights. Notwithstanding...
May 30, 2023 Key Takeaways from the 21st Annual Biomed Israel Conference By Ben Cohen The 21st annual Biomed Israel Conference, attended by thousands of industry leaders from 45 countries, presented a juxtaposition of...
May 23, 2023 2023 ACC Life Sciences Conference: Structuring Considerations for Biotechs By Jeff Jay Jake Silvers The Association of Corporate Counsel hosted its annual Life Sciences Conference from May 9-11, 2023, which featured presentations from a...
Mar 30, 2023 SEC Issues Interpretive Guidance on Tender Offers By Jeremy Barr Michael Lam The Staff of SEC’s Division of Corporation Finance (the “Staff”) recently issued a series of Compliance and Disclosure Interpretations...
Mar 20, 2023 When Do We Say What On Pay? By Pamela Marcogliese Elizabeth Bieber Daniel Fox Zhanqi Xu +1 more... Show less It’s that time again. For companies that are required to hold advisory shareholder “say-on-pay” votes on their executive compensation,...
Mar 10, 2023 You’ve been warned – FTC’s first merger closing statement in over three years sends a reminder to companies that antitrust is only one consideration By Christine Lyon Jamillia Ferris Meghan Rissmiller Rod Carlton Daniel Wylde Rikki Haria +3 more... Show less In a rare move on February 27, 2023, the Federal Trade Commission (FTC) issued its first statement akin to a closing statement since...
Mar 06, 2023 Bridging Valuation Gaps in Public M&A in the Pharma, Biotech, and Other Life Sciences Industries By Jenny Hochenberg Adam Golden Acquisitions of public companies in pharma, biotech, and other life sciences industries are increasingly using deal structures designed...
Jan 30, 2023 The Drug Pricing Landscape in 2023: Renewed Pressure for Pricing Reform By Adam Golden Tanny Kang Emily Parfitt Kristen Riemenschneider +1 more... Show less For over a decade, industry watchdogs, patient groups and various lawmakers have been calling for drug pricing reform—initially with...